KLF5 and prostate carcinoma: Knockin of the Klf5KR mutant successfully interrupted Klf5 acetylation in Pten-deficient mouse prostates (Figure 1, A and B), providing an ideal model with which to test how Klf5 acetylation affects Pten-deficient prostate cancer.